Here is a review of the effectiveness of fidaxomicin vs vancomycin for CDI treatment in populations with immunocompromised conditions.
Eunice Kim, PharmD
Advertisement
Kim is a PGY2 infectious diseases pharmacy resident at Beth Israel Deaconess Medical Center in Boston, Massachusetts. Kim is a member of the Society of Infectious Diseases Pharmacists.
Articles by Eunice Kim, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
Nearly 1 in 5 Urinary Tract Infections in Southern California Linked to Contaminated Meat
2
Moderna Discontinues Development of Vaccine for Congenital CMV After Not Meeting Primary Efficacy Endpoint
3
High Continued Adherence of Lenacapavir in Individuals Who Use Substances and Alcohol
4
Risk Stratification, Testing, and Treatment in Recurrent Clostridioides difficile
5
